On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma
March 17, 2023
March 17, 2024
This activity is jointly provided by Bio Ascend and PACE.
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma.
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.
Upon completion of this activity, participants should be better able to:
- Discuss patient-related and disease-related factors that impact the selection of therapy for patients with relapsed/refractory MM
- Review the rationale for targeting BCMA in patients with MM, as well as current and emerging approaches that target BCMA, including CAR T-cells, bispecific antibodies, and antibody-drug conjugates
- Evaluate strategies to manage adverse events that may be encountered with the use of anti-BCMA therapies
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bio Ascend LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Topics of Discussion
Module 1: Introduction and Rationale for Targeting BCMA on MM Cells
Module 2: BCMA-Targeted CAR T-cells
Module 3: BCMA-Targeted Antibody-Drug Conjugates (ADCs)
Module 4: BCMA-Targeted Bispecifics
Faculty and Disclosure Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Joseph Mikhael, MD, MEd, FRCPC, FACP - Moderator
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Consultant, Advisor, Speaker: Amgen, BMS, Janssen, Karyopharm, Sanofi, Takeda
Suzanne Lentzsch, MD, PhD
Professor of Medicine at Columbia University
Director, Multiple Myeloma and Amyloidosis Service
Associate Editor, Journal of Clinical Oncology
Columbia University Medical Center
New York, New York
Royalties or Patent Beneficiary: Caelum Bioscience
Consultant, Advisor, Speaker: Takeda, Regeneron, Janssen, GSK, Sanofi, BMS, Adaptive
Individual publicly traded stocks and stock options: Magenta, Poseida
Researcher: Zentalis, Sanofi
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Consultant, Advisor, Speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Curio Sciences Bio, Janssen, Legend Biotech, Merck, Oncopeptides, Pfizer, PrecisionBio, Karyopharm
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Bio Ascend LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the evaluation 4) complete the post-test with a passing score of 75% or better.
Upon successfully completing the post-test and evaluation, your certifcate will be made available immediately.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
For CME questions please contact: email@example.com.
For additional information about the accreditation of this activity, please visit https://partnersed.com